CMS restricts coverage of Alzheimer’s drug Aduhelm to clinical trials
By
Alicia Lasek
Apr 08, 2022
Coverage of aducanumab (Aduhelm) is officially limited to clinical trials only, the agency announced Thursday. Most stakeholders have called for restricted use while more efficacy and safety data is gathered,...
Becerra orders CMS to rethink $22 Medicare Part B premium price hike tied to Aduhelm
By
Alicia Lasek
Jan 11, 2022
With the 50% price drop of Aduhelm on January 1, there is good reason for CMS to reassess a hefty proposed premium hike for 2022, the U.S. health secretary said. On Wednesday, CMS is expected to announce...